ClearPoint Neuro logo

ClearPoint NeuroNASDAQ: CLPT

Profile

Sector:

Healthcare

Country:

United States

IPO:

22 May 2012

Next earnings report:

12 March 2025

Last dividends:

N/A

Next dividends:

N/A
$302.33 M
-25%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector
-18%vs. 3y high
92%vs. sector
-54%vs. 3y high
77%vs. sector

Price

after hours | 11 min ago
$10.96-$0.01(-0.09%)

Dividend

No data over the past 3 years
$8.12 M$8.23 M
$8.12 M-$4.97 M

Analysts recommendations

Institutional Ownership

CLPT Latest News

ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
accesswire.com13 November 2024 Sentiment: POSITIVE

Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

ClearPoint Neuro: Near-Term Volatility Is No Concern
seekingalpha.com10 November 2024 Sentiment: POSITIVE

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution.

ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024
globenewswire.com17 October 2024 Sentiment: POSITIVE

SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close.

ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock?
zacks.com15 October 2024 Sentiment: POSITIVE

ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ClearPoint Neuro Announces Early Repayment of $10 Million Note
globenewswire.com26 August 2024 Sentiment: POSITIVE

ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics

ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade)
seekingalpha.com14 August 2024 Sentiment: POSITIVE

ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data.

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
zacks.com07 August 2024 Sentiment: POSITIVE

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
globenewswire.com17 July 2024 Sentiment: POSITIVE

SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close.

Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength?
zacks.com10 July 2024 Sentiment: POSITIVE

ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment
zacks.com03 June 2024 Sentiment: POSITIVE

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

  • 1(current)
  • 2

What type of business is ClearPoint Neuro?

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

What sector is ClearPoint Neuro in?

ClearPoint Neuro is in the Healthcare sector

What industry is ClearPoint Neuro in?

ClearPoint Neuro is in the Medical Devices industry

What country is ClearPoint Neuro from?

ClearPoint Neuro is headquartered in United States

When did ClearPoint Neuro go public?

ClearPoint Neuro initial public offering (IPO) was on 22 May 2012

What is ClearPoint Neuro website?

https://www.clearpointneuro.com

Is ClearPoint Neuro in the S&P 500?

No, ClearPoint Neuro is not included in the S&P 500 index

Is ClearPoint Neuro in the NASDAQ 100?

No, ClearPoint Neuro is not included in the NASDAQ 100 index

Is ClearPoint Neuro in the Dow Jones?

No, ClearPoint Neuro is not included in the Dow Jones index

When was ClearPoint Neuro the previous earnings report?

No data

When does ClearPoint Neuro earnings report?

The next expected earnings date for ClearPoint Neuro is 12 March 2025